Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases.
Hecht JR, Raman SS, Chan A, Kalinsky K, Baurain JF, Jimenez MM, Garcia MM, Berger MD, Lauer UM, Khattak A, Carrato A, Zhang Y, Liu K, Cha E, Keegan A, Bhatta S, Strassburg CP, Roohullah A. Hecht JR, et al. Among authors: lauer um. ESMO Open. 2023 Apr;8(2):100884. doi: 10.1016/j.esmoop.2023.100884. Epub 2023 Feb 28. ESMO Open. 2023. PMID: 36863095 Free PMC article. Clinical Trial.
NUT carcinoma in pediatric patients: Characteristics, therapeutic regimens, and outcomes of 11 cases registered with the German Registry for Rare Pediatric Tumors (STEP).
Flaadt T, Wild H, Abele M, Frühwald M, Dirksen U, Classen CF, Seitz C, Redlich A, Lauer UM, Kloker L, Kratz C, Schneider DT, Brecht IB. Flaadt T, et al. Among authors: lauer um. Pediatr Blood Cancer. 2024 Mar;71(3):e30821. doi: 10.1002/pbc.30821. Epub 2023 Dec 26. Pediatr Blood Cancer. 2024. PMID: 38148490
Radiosensitizing Favors Response to Peptide Receptor Radionuclide Therapy in Patients With Highly Proliferative Neuroendocrine Malignancies: Preliminary Evidence From a Clinical Pilot Study.
Trautwein NF, Hinterleitner C, Kiefer LS, Singer S, Mattern S, Schwenck J, Reischl G, Sipos B, Lauer UM, Dittmann H, Zender L, la Fougère C, Hinterleitner M. Trautwein NF, et al. Among authors: lauer um. Clin Nucl Med. 2024 Mar 1;49(3):207-214. doi: 10.1097/RLU.0000000000005006. Epub 2024 Jan 23. Clin Nucl Med. 2024. PMID: 38271237
Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3.
Hinterleitner M, Pfeiffer R, Trautwein NF, Sipos B, Singer S, Nadalin S, Königsrainer A, Lauer UM, la Fougère C, Zender L, Hinterleitner C. Hinterleitner M, et al. Among authors: lauer um. Front Endocrinol (Lausanne). 2024 Jan 8;14:1285529. doi: 10.3389/fendo.2023.1285529. eCollection 2023. Front Endocrinol (Lausanne). 2024. PMID: 38260136 Free PMC article.
150 results